Simiso Sokhela, Samanta Lalla-Edward, Mark J Siedner, Mohammed Majam, Willem Daniel Francois Venter
{"title":"Roadmap for Achieving Universal Antiretroviral Treatment.","authors":"Simiso Sokhela, Samanta Lalla-Edward, Mark J Siedner, Mohammed Majam, Willem Daniel Francois Venter","doi":"10.1146/annurev-pharmtox-052020-094321","DOIUrl":null,"url":null,"abstract":"<p><p>Modern antiretroviral therapy safely, potently, and durably suppresses human immunodeficiency virus (HIV) that, if left untreated, predictably causes acquired immunodeficiency syndrome (AIDS), which has been responsible for tens of millions of deaths globally since it was described in 1981. In one of the most extraordinary medical success stories in modern times, a combination of pioneering basic science, innovative drug development, and ambitious public health programming resulted in access to lifesaving, safe drugs, taken as an oral tablet daily, for most of the world. However, substantial challenges remain in the fields of prevention, timely access to diagnosis, and treatment, especially in pediatric and adolescent patients. As HIV-positive adults age, treating their comorbidities will require understanding the course of different chronic diseases complicated by HIV-related and antiretroviral toxicities and finding potential treatments. Finally, new long-acting antiretrovirals on the horizon promise exciting new options in both the prevention and treatment fields.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"99-117"},"PeriodicalIF":11.2000,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10807407/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual review of pharmacology and toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/annurev-pharmtox-052020-094321","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Modern antiretroviral therapy safely, potently, and durably suppresses human immunodeficiency virus (HIV) that, if left untreated, predictably causes acquired immunodeficiency syndrome (AIDS), which has been responsible for tens of millions of deaths globally since it was described in 1981. In one of the most extraordinary medical success stories in modern times, a combination of pioneering basic science, innovative drug development, and ambitious public health programming resulted in access to lifesaving, safe drugs, taken as an oral tablet daily, for most of the world. However, substantial challenges remain in the fields of prevention, timely access to diagnosis, and treatment, especially in pediatric and adolescent patients. As HIV-positive adults age, treating their comorbidities will require understanding the course of different chronic diseases complicated by HIV-related and antiretroviral toxicities and finding potential treatments. Finally, new long-acting antiretrovirals on the horizon promise exciting new options in both the prevention and treatment fields.
现代抗逆转录病毒疗法能够安全、有效、持久地抑制人体免疫缺陷病毒(HIV),如果不及时治疗,就会导致获得性免疫缺陷综合征(艾滋病),自 1981 年艾滋病被描述以来,全球已有数千万人死于艾滋病。在现代最非凡的医学成功故事中,开创性的基础科学、创新性的药物开发和雄心勃勃的公共卫生计划相结合,使世界上大多数人都能获得救命的安全药物,每天口服一片。然而,在预防、及时诊断和治疗方面,尤其是在儿童和青少年患者中,仍然存在巨大的挑战。随着 HIV 阳性成人患者年龄的增长,治疗他们的合并症需要了解因 HIV 相关和抗逆转录病毒毒性而复杂化的不同慢性疾病的病程,并找到潜在的治疗方法。最后,即将问世的新型长效抗逆转录病毒药物为预防和治疗领域带来了令人兴奋的新选择。
期刊介绍:
Since 1961, the Annual Review of Pharmacology and Toxicology has been a comprehensive resource covering significant developments in pharmacology and toxicology. The journal encompasses various aspects, including receptors, transporters, enzymes, chemical agents, drug development science, and systems like the immune, nervous, gastrointestinal, cardiovascular, endocrine, and pulmonary systems. Special topics are also featured in this annual review.